Zeposia (ozanimod)
Multiple sclerosis
CommercialApproved
Key Facts
About Bristol Myers Squibb
Bristol Myers Squibb operates as a premier global biopharmaceutical company with a mission to transform patients' lives through science. The company maintains leadership positions in oncology, hematology, cardiovascular, and immunology therapeutic areas with blockbuster products and innovative treatment modalities. BMS employs a research strategy rooted in causal human biology and diverse platform technologies to deliver first- and best-in-class medicines to patients worldwide.
View full company profileTherapeutic Areas
Other Multiple sclerosis Drugs
| Drug | Company | Phase |
|---|---|---|
| Copaxone (glatiramer acetate) | Teva Pharmaceutical Industries | Commercial |
| Multiple Sclerosis Portfolio | Biogen | Commercial |
| Kesimpta (ofatumumab) | Genmab | Approved |
| Glatiramer Acetate (Generic Copaxone) | Dr. Reddy's Laboratories | Approved |
| Glatiramer Acetate | Cipla | Commercial |
| Interferon β-1a | Bachem | Commercial |
| KYV-101 | Kyverna Therapeutics | Phase 1/2 |
| Azer-cel (PBCAR0191) | Precision BioSciences | Phase 1/2 |
| CYMS101 | FibroBiologics | Pre-clinical / Limited Clinical |